Expression of anti-cardiolipin antibodies and inflammatory associated factors in patients with schizophrenia

Psychiatry Research

Volumn 187, Issue 3, 2011, Pages 341-346

  Chang, Sheng Huang ^a,b   Chiang, Szu Yi ^c   Chiu, Chun Ching ^a,d   Tsai, Chun Chou ^a   Tsai, Huei Huang ^b   Huang, Chih Yang ^e,f   Hsu, Tsai Ching ^a,g   Tzang, Bor Show ^a,g  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b Tsaotun Psychiatric Center   (Taiwan)

^c Hualien Hospital   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f ASIA UNIVERSITY   (Taiwan)

^g CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Autoimmune disorder; Interleukin (IL); Schizophrenic (SZ); TLR (toll like receptor)

Indexed keywords

AMISULPRIDE; BIPERIDEN; CARBAMAZEPINE; CARDIOLIPIN ANTIBODY; CLONAZEPAM; CLOTIAPINE; CLOZAPINE; ESTAZOLAM; FLUPENTIXOL; FLUVOXAMINE MALEATE; GELATINASE B; GLIBENCLAMIDE; HALOPERIDOL; INTERLEUKIN 10; INTERLEUKIN 6; LORAZEPAM; MESSENGER RNA; NEUROLEPTIC AGENT; PROPRANOLOL; QUETIAPINE; SULPIRIDE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 5; VALPROATE SEMISODIUM; ZOTEPINE;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; MALE; MONOCYTE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANALYSIS OF VARIANCE; ANTIBODIES, ANTICARDIOLIPIN; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MONOCYTES; RNA, MESSENGER; SCHIZOPHRENIA; TOLL-LIKE RECEPTORS;

EID: 79954568225     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.04.049     Document Type: Article

References (37)

1. Abdollahi-Roodsaz S., Joosten L.A., Roelofs M.F., Radstake T.R., Matera G., Popa C., van der Meer J.W., Netea M.G., van den Berg W.B. Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis & Rheumatism 2007, 56:2957-2967.
2. Ainiala H., Hietaharju A., Dastidar P., Loukkola J., Lehtimäki T., Peltola J., Korpela M., Heinonen T., Nikkari S.T. Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities. Arthritis & Rheumatism 2004, 50:858-865.
3. Barrat F.J., Coffman R.L. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunological Reviews 2008, 223:271-283.
4. Bergen J.R., Grinspoon L., Pyle H.M., Martinez J.L., Pennell R.B. Immunologic studies in schizophrenic and control subjects. Biological Psychiatry 1980, 15:369-379.
5. Brenner B., Metz L. Symptomatic antiphospholipid antibody after neuroleptic drugs. Harefuah 1995, 128:416-417.
6. Christensen S.R., Shupe J., Nickerson K., Kashgarian M., Flavell R.A., Shlomchik M.J. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006, 25:417-428.
7. Cronstein B.N. Interleukin-6-a key mediator of systemic and local symptoms in rheumatoid arthritis. Bulletin of the NYU Hospital for Joint Diseases 2007, 65(Suppl 1):S11-S15.
8. De Jager P.L., Richardson A., Vyse T.J., Rioux J.D. Genetic variation in toll-like receptor 9 and susceptibility to systemic lupus erythematosus. Arthritis & Rheumatism 2006, 54:1279-1282.
9. Eaton W.W., Byrne M., Ewald H., Mors O., Chen C.Y., Agerbo E., Mortensen P.B. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. American Journal of Psychiatry 2006, 163:521-528.
10. Fudenberg H.H., Whitten H.D., Merler E., Farmati O. Is schizophrenia an immunologic receptor disorder?. Medical Hypotheses 1983, 12:85-93.
11. Fujimoto M., Serada S., Naka T. Role of IL-6 in the development and pathogenesis of CIA and EAE. Nihon Rinsho Meneki Gakkai Kaishi 2008, 31(2):78-84. Apr.
12. Ganguli R., Rabin B.S., Belle S.H. Decreased interleukin-2 production in schizophrenic patients. Biological Psychiatry 1989, 26:427-430.
13. Ganguli R., Brar J.S., Rabin B.S. Immune abnormalities in schizophrenia: evidence for the autoimmune hypothesis. Harvard Review of Psychiatry 1994, 2:70-83.
14. Gilmore J.H., Jarskog L.F. Exposure to infection and brain development: cytokines in the pathogenesis of schizophrenia. Schizophrenia Research 1997, 24:365-367.
15. Hägg S., Spigset O. Antipsychotic-induced venous thromboembolism: a review of the evidence. CNS Drugs 2002, 16:765-776.
16. Hägg S., Spigset O., Soderstroem T.G. Association of venous thromboembolism and clozapine. Lancet 2000, 355:1155-1156.
17. Hawn T.R., Wu H., Grossman J.M., Hahn B.H., Tsao B.P., Aderem A. A stop codon polymorphism of Toll-like receptor 5 is associated with resistance to systemic lupus erythematosus. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:10593-10597.
18. Heath R.G., McCarron K.L., O'Neil C.E. Antiseptal brain antibody in IgG of schizophrenic patients. Biological Psychiatry 1989, 25:725-733.
19. Henneberg A.E., Horter S., Ruffert S. Increased prevalence of antibrain antibodies in the sera from schizophrenic patients. Schizophrenia Research 1994, 14:15-22.
20. Hsu T.C., Chen Y.C., Lai W.X., Chiang S.Y., Huang C.Y., Tzang B.S. Beneficial effects of treatment with cystamine on brain in NZB/W F1 mice. European Journal of Pharmacology 2008, 591:307-314.
21. Knudsen J.F., Kortepeter C., Dubitsky G.M., Ahmad S.R., Chen M. Antipsychotic drugs and venous thromboembolism. Lancet 2000, 356:252-253.
22. Lieberman J.A. Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia. Journal of Clinical Psychiatry 1999, 60(Suppl 12):9-12.
23. Liperoti R., Pedone C., Lapane K.L., Mor V., Bernabei R., Gambassi G. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Archives of Internal Medicine 2005, 165:2677-2682.
24. McAllister C.G., Rapaport M.H., Pickar D., Podruchny T.A., Christison G., Alphs L.D., Paul S.M. Increased numbers of CD5+ B lymphocytes in schizophrenic patients. Archives of General Psychiatry 1989, 46:890-894.
25. Mukherjee S., Mahadik S.P., Korenovsky A., Laev H., Schnur D.B., Reddy R. Serum antibodies to nicotinic acetylcholine receptors in schizophrenic patients. Schizophrenia Research 1994, 12:131-136.
26. Muller N., Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotoxicity Research 2006, 10:131-148.
27. Naudin J., Mege J.L., Azorin J.M., Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophrenia Research 1996, 20:269-273.
28. Pandey R.S., Gupta A.K., Chaturvedi U.C. Autoimmune model of schizophrenia with special reference to antibrain antibodies. Biological Psychiatry 1981, 16:1123-1136.
29. Robak E., Wierzbowska A., Chmiela M., Kulczycka L., Sysa-Jedrejowska A., Robak T. Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus. Mediators. Inflammation 2006, 1:17898.
30. Sammaritano L.R., Gharavi A.E. Antiphospholipid antibody syndrome. Clinical Laboratory Medicine 1992, 12:41-59.
31. Savarese E., Steinberg C., Pawar R.D., Reindl W., Akira S., Anders H.J., Krug A. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis & Rheumatism 2008, 58:1107-1115.
32. Shen H., Li R., Xiao H., Zhou Q., Cui Q., Chen J. Higher serum clozapine level is associated with increased antiphospholipid antibodies in schizophrenia patients. Journal of Psychiatric Research 2009, 43:615-619.
33. Shinitzky M., Deckmann M., Kessler A., Sirota P., Rabbs A., Elizur A. Platelet autoantibodies in dementia and schizophrenia. Possible implication for mental disorders. Annals of the New York Academy of Sciences 1991, 621:205-217.
34. Sirota P., Firer M.A., Schild K., Tanay A., Elizur A., Meytes D., Slor H. Autoantibodies to DNA in multicase families with schizophrenia. Biological Psychiatry 1993, 33:450-455.
35. Smith R.S. The immune system is a key factor in the etiology of psychosocial disease. Medical Hypotheses 1991, 34:49-57.
36. Theodoropoulou S., Spanakos G., Baxevanis C.N., Economou M., Gritzapis A.D., Papamichail M.P., Stefanis C.N. Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophrenia Research 2001, 47:13-25.
37. Zhang X.Y., Zhou D.F., Zhang P.Y., Wu G.Y., Cao L.Y., Shen Y.C. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophrenia Research 2002, 57:247-258.